Fig. 1 (abstract O12).
RCC - AM0010 + Anti-PD-1. Anti-PD-1 naive RCC were treated with AM0010 in combination with nivolumab (black) or pembrolizumab (red). ORR 41%, DCR 85%
Fig. 1 (abstract O12). | Journal for ImmunoTherapy of Cancer